MFA031 is a first-in-class TIGIT agonist–IL-10 fusion therapeutic designed to restore immune balance through targeted immune regulation. By combining a proprietary TIGIT agonistic antibody with an engineered IL-10 cytokine, MFA031 selectively promotes the expansion and function of regulatory T cells (Tregs), key mediators of immune tolerance. This targeted approach is designed to suppress pathological immune responses while preserving protective immunity, offering a differentiated treatment strategy for autoimmune and inflammatory diseases.
Key Features